Michael Robert A. 4

What Happened
Michael Robert A., CEO of AbbVie, was reported as acquiring a total of 163,690 shares on Feb 18, 2026 through multiple awards (price $0.00). The awards break down as: 33,833 shares, 12,030 shares, 14,452 shares, 22,124 shares, plus a derivative award covering 81,251 shares. The performance-based awards had their vesting conditions certified by AbbVie’s Compensation Committee; the shares will be issued on Feb 28, 2026. The 81,251-share derivative is an employee stock option that vests/exercises in annual increments (27,084 on 2/18/2027, 27,084 on 2/18/2028, 27,083 on 2/18/2029).

Key Details

• Transaction date(s): February 18, 2026 (reported on Form 4 filed Feb 20, 2026). Price: $0.00 (award/grant). Aggregate shares: 163,690.
• Footnotes: F1–F4 = performance-vesting share/RSU awards (granted in 2023–2025) released upon certification of performance goals; F5 = employee stock option under AbbVie’s 2013 Incentive Stock Program.
• Shares issuance: awards to be issued on February 28, 2026.
• Shares owned after transaction: not provided in the excerpt of the filing.
• Filing timeliness: Form 4 filed Feb 20, 2026 for Feb 18, 2026 transactions (appears timely under Section 16 two-business-day rule).

Context

• These were awards/grants (code A) tied to previously granted performance-based awards and an option — not open-market purchases or sales. Awards granted upon certification do not by themselves indicate a buy/sell market signal; they reflect company compensation and performance achievement.
• The derivative item is an option with future exercise dates (2027–2029), not an immediate sale or cashless exercise.